DD THREAD ON $TAUG , 5 upcoming catalysts that can cause it to spike, and why it is a COVID-PROOF stock.
WORTH THE READ

TAUG has announced growth in sales for their 4th consecutive month now- after starting this business segment in just over a year ago and have almost $1M of
inventory fully paid for and just paid off their debt. Although this is good news itself, I suspect this is just the beginning for this company, and the majority of their profits will be used to fund other business activities to achieve maximum growth.
1) Estimated earnings date for $TAUG are July 2nd, and regardless of earnings, this company is tremendously undervalued with only a sub $4M market cap and trading under 4 cents per share, when in March 2019 it reached highs of 36 cents per share (800%+ return).
it can be trading at a valuation as a pharmaceutical or biotech company would, as there are several catalysts I will explain below (this company loves to be transparent with their investors and put out press releases whenever there is something to disclose
NOW HERE IS WHERE THINGS GET INTERESTING AS I DUG DEEPER

Lyle Arnold, Ph.D., Aegea’s founder and CEO, IS ALSO Senior Vice President of Research & Development and Chief Scientific Officer at BIOCEPT ( TICKER $BIOC ), recent supernova stock during the pandemic
This suggests that this partnership with Aegea could be the first domino to fall for countless other relationships to form in the industry and provide incredible results for the company as they will essentially have access to whatever connections Biocept currently has that's
given them a $100M Market cap.

[ https://biocept.com/about/management/]( https://biocept.com/about/management/) you can see Lyle Arnold listed on the Biocept management team, and read his quotes on their work with $TAUG in the other two PRs above.
The change of name reflects the Company’s decision to concentrate this subsidiary’s focus on the development of a pharmaceutical product line to address nausea symptoms related to Chemotherapy treatment in patients. The Company has commenced discussions with the appropriate pro
-fessionals and experts needed in this regard, including matters related to clinical trials, submissions to any regulatory agencies, including the Food and Drug Administration (“FDA”), and for such other customary submissions, reviews and approvals as and when needed
5) Although the pharmaceutical potential and side of business could possibly bring this stock to $1 itself, the retail and ecommerce business for the company is booming, gaining access to new marketplaces and continuing growth in already established market places. This hasn't
6) STRICTLY MY OPINION/SPECULATION

Once this stock meets qualifications I’d have to imagine it gets listed on the NASDAQ or NYSE which will brings in TONSSSSS of new eyes/investors. No company wants to be a penny stock/OTC forever. $TAUG let me know what y’all think
You can follow @swingtr8er.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.